Challenge Grant Recipients Moving Forward
The Pancreatic Cancer Collective awarded four teams a second round of New Therapies Challenge Grants, to further develop new pancreatic cancer treatment.
Exploiting DNA Mutations For Pancreatic Cancer Treatment
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
Decoding the Differences between At-Home and Medical Genetic Testing
Genetic counselors Jill Stopfer and Heather Hampel explain the differences between at-home and medical genetic testing, including precision and knowledge.
Clinical Trial For OncoTreat Being Developed
Researcher Kenneth Olive is developing OncoTreat, a method matches a patient's tumor to the most effective drugs for their pancreatic cancer.
Looking Back at the Year in Research: 2019
The research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
Tumor RNA Testing Leads to Treatment with a New Drug
When treatment stopped working for Adam Deal, genetic testing of his tumor RNA found a mutation that made him eligable to try a new drug.
Radiation Therapy To Fight Pancreatic Cancer
Dr. Smith Apisarnthanarax, a radiation oncologist, details the different types of radiation therapy given to pancreatic cancer patients.
Platinum-Based Therapy Can Significantly Improve Survival for Some Pancreatic Cancer Patients
Dr. Michael Pishvaian explains how platinum-based therapy can improve the survival of pancreatic cancer patients with a specific mutation.
Immunotherapy to Attack a Common Pancreatic Cancer Mutation
Researchers are testing a type of immunotherapy to attack a variant of the KRAS mutation; KRAS mutations occur in almost all pancreatic cancers.
Representing Genetic and Clinical Diversity in Pancreatic Cancer
Dr. Kentaro Sudo explores the possible causes for different responses to drugs among ethnic groups, pointing to the need for clinical diversity in trials.
